2023-07-19 11:47:00
Combining the pancreatic cancer vaccine GVAX, the immunotherapy nivolumab and urelemab, and agonist anti-CD137 antibody treatment is safe, increases the number of cancer-killing immune T cells in tumors, and appears effective when given two times. weeks before cancer removal surgery.
Combining the pancreatic cancer vaccine GVAX, the immunotherapy nivolumab and urelemab, and agonist anti-CD137 antibody treatment is safe, increases the number of cancer-killing immune T cells in tumors, and appears effective when given two times. weeks before the … + read more
A gene present at high levels worsens the prognosis of lung and pancreatic cancer
Researchers from the Cima Universidad de Navarra suggest that its blocking will facilitate the development of more effective treatments. + read more
The Clínic celebrates 40 years of the first pancreas transplant in the national territory
It is the hospital in Spain that performs the most pancreas transplants. + read more
They find the possible causes of why the effect of immunotherapy in pancreatic cancer differs between men and women
Evidence has shown that there are biological sex-linked differences in the male and female immune systems that, among other effects, determine how tumors grow and the body’s ability to defend itself against them. + read more
2023-07-19 09:47:00
#pancreatic #cancer #vaccine #immunotherapy #antibodies #safe #effective
